- |||||||||| cisplatin/vinblastine/SHAO-FA (INT230-6) / Intensity Therap
Trial primary completion date, Metastases: KEYNOTE-A10: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (clinicaltrials.gov) - Aug 8, 2017 P1/2, N=60, Recruiting, N=138 --> 34 | Recruiting --> Suspended | Recruiting --> Suspended Trial primary completion date: Jul 2018 --> Jul 2019
- |||||||||| Xalkori (crizotinib) / Pfizer
Enrollment closed, Trial primary completion date, Metastases: CREATE: Cross-tumoral Phase 2 With Crizotinib (clinicaltrials.gov) - Aug 7, 2017 P2, N=582, Active, not recruiting, Initiation date: Mar 2014 --> Aug 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017
- |||||||||| Avastin (bevacizumab) / Roche
Trial primary completion date: Optune (clinicaltrials.gov) - Aug 7, 2017 P2, N=85, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Apr 2018 --> Aug 2020
- |||||||||| Journal: Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma. (Pubmed Central) - Aug 6, 2017
The drug produces no survival benefit in a tail vein injection model, supporting the hypothesis that WNT974 inhibits early steps in the metastatic cascade, such as migration and invasion. Our findings strongly implicate Wnt signaling in the early steps of ES metastasis and demonstrate that WNT974 has the potential to significantly improve the survival of ES patients through the specific inhibition of metastasis.
- |||||||||| Lartruvo (olaratumab) / Eli Lilly
Review, Journal: Olaratumab for the treatment of soft tissue sarcoma. (Pubmed Central) - Aug 5, 2017 Despite recent advances in treatment beyond first line - with the FDA approval of pazopanib, eribulin and trabectidin - overall survival for patients with metastatic disease remains in the region of 12-19 months...Ongoing trials are underway to further demonstrate the mechanism of action. This review will document the studies involved in the development of olaratumab in the treatment of soft tissue sarcomas.
- |||||||||| Psoralen / EMD Serono
Journal: X-Ray Psoralen Activated Cancer Therapy (X-PACT). (Pubmed Central) - Aug 3, 2017 Overall these studies demonstrate a potential therapeutic effect for X-PACT, and provide a foundation and rationale for future studies. In summary, X-PACT represents a novel treatment approach in which well-tolerated low doses of x-ray radiation are delivered to a specific tumor site to generate UVA light which in-turn unleashes both short- and potentially long-term antitumor activity of photo-active therapeutics like psoralen.
- |||||||||| abexinostat (CG-781) / Xynomic, Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors (clinicaltrials.gov) - Aug 1, 2017 P1, N=52, Active, not recruiting, N=74 --> 113 Recruiting --> Active, not recruiting | N=70 --> 52 | Trial primary completion date: Apr 2015 --> Jan 2019
- |||||||||| Gilotrif (afatinib) / Boehringer Ingelheim
Phase classification, Monotherapy, Pan tumor: Trial of Afatinib in Pediatric Tumours (clinicaltrials.gov) - Aug 1, 2017 P1/2, N=55, Recruiting, Recruiting --> Active, not recruiting | N=70 --> 52 | Trial primary completion date: Apr 2015 --> Jan 2019 Phase classification: P1 --> P1/2
- |||||||||| Journal: Cancer therapy directed by comprehensive genomic profiling: a single center study. (Pubmed Central) - Jul 29, 2017
By calculating matching scores, based on the number of drug matches and genomic aberrations per patient, we found that high scores were independently associated with a greater frequency of stable disease {greater than or equal to}6 months/partial/complete remission (22% (high scores) vs. 9% (low scores), p=0.024), longer time-to-treatment failure (hazard ratio [HR]=0.52, 95% confidence interval [CI]=0.36-0.74, p=0.0003), and survival (HR=0.65, CI=0.43-1.0, p=0.05). Collectively, this study offers a clinical proof of concept for the utility of CGP in assigning therapy to patients with refractory malignancies, especially in those patients with multiple genomic aberrations for whom combination therapies could be implemented.
- |||||||||| Turalio (pexidartinib) / Daiichi Sankyo
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: KEYNOTE-103: A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov) - Jul 28, 2017 P1/2, N=80, Active, not recruiting, Recruiting --> Active, not recruiting | Initiation date: Jul 2014 --> Nov 2014 Recruiting --> Active, not recruiting | N=400 --> 80 | Trial primary completion date: May 2019 --> May 2018 | Recruiting --> Active, not recruiting | N=400 --> 80 | Trial primary completion date: May 2019 --> May 2018
- |||||||||| Stivarga (regorafenib) / Bayer
Trial primary completion date, Stroma, Metastases: The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib (clinicaltrials.gov) - Jul 28, 2017 P4, N=14, Recruiting, Recruiting --> Active, not recruiting | N=400 --> 80 | Trial primary completion date: May 2019 --> May 2018 | Recruiting --> Active, not recruiting | N=400 --> 80 | Trial primary completion date: May 2019 --> May 2018 Trial primary completion date: Jun 2017 --> Dec 2017
- |||||||||| Biomarker, Enrollment open, BRCA Biomarker, PARP Biomarker, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - Jul 28, 2017
P2, N=1500, Recruiting, Initiation date: Jun 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Biomarker, BRCA Biomarker, PARP Biomarker, Metastases: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) (clinicaltrials.gov) - Jul 27, 2017 P2, N=49, Recruiting,
- |||||||||| Tazverik (tazemetostat) / Eisai, Ipsen
Biomarker, Enrollment open, Metastases: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (clinicaltrials.gov) - Jul 27, 2017 P2, N=49, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
|